# INSIGHT



Bourne Partners

#### **CDMO – Transaction Comps**


#### **CDMO - Transaction Comps**

USD in	millions
--------	----------

Announced Date	Target	Target Description	Buyer	Geographic Location	Enterprise Value	LTM Revenue	LTM EBITDA	EV / LTM Revenue	EV / LTM EBITDA
Aug-19	Cambrex Corporation	Operates as a CDMO for the development and commercialization of new and generic therapeutics worldwide.	Permira Advisers	USA	\$2,545.2	\$574.1	\$146.6	4.4x	17.4x
Apr-19	Paragon Bioservices <sup>1</sup>	Operates as a CDMO that focuses on the development and manufacturing of biopharmaceuticals	Catalent Pharma Solutions	USA	1,200.0	101.0	56.0	11.9x	21.4x
Mar-19	Biogen (Denmark) Manufacturing Facility	Biopharmaceutical CDMO facility with 90,000L biologic production capacity	Fujifilm Diosynth Biotechnologies	Denmark	890.0	NA	NA	NA	NA
Mar-19	Brammer Bio	CDMO developing and manufacturing cell and gene therapies	Thermo Fisher	USA	1,700.0	NA	NA	NA	NA
Nov-18	Avista Pharma Solutions <sup>2</sup>	CDMO offering services including analytical testing, API and drug product development, early stage discovery, and microbiology testing support	Cambrex Corporation	USA	252.0	65.0	NA	3.9x	NA
Jul-18	AMPAC Fine Chemicals <sup>3</sup>	Operates as a custom manufacturer of APIs and registered intermediates for the pharmaceutical industry	SK Holdings	USA	455.0	200.0	NA	2.3x	NA
Jul-18	Halo Pharma	Provides contract development and manufacturing services in various dosage forms and drug delivery platforms	Cambrex Corporation	USA	425.0	105.0	27.0	4.0x	15.7x
Sep-17	Cook Pharmica	Provides contract development and manufacturing services to pharmaceutical and biopharmaceutical companies	Catalent Pharma Solutions	USA	950.0	177.8	NA	5.3x	NA
Jul-17	Aptuit	Provides drug discovery and development services, as well as API development and manufacturing services	Evotec	USA	300.0	92.9	11.6	3.2x	25.8x
Jun-17	PCAS SA	Provides chemical and analytical development and custom manufacturing services	Novacap	France	335.9	243.7	19.7	1.4x	17.0x
Jun-17	Albany Molecular Research	Contract research and manufacturing company that provides integrated drug discovery, development, and manufacturing	The Carlyle Group	USA	1,593.5	628.7	71.8	2.5x	22.2x
May-17	Patheon	Provides outsourced pharmaceutical development and manufacturing services	Thermo Fisher	USA	7,205.3	1,933.0	351.2	3.7x	20.5x

#### Notes.

NA - Not Available





<sup>1) &</sup>quot;Biopharma Dive": 2018 Revenue Estimate; "Catalent: Paragon Gene Therapy Acquisition Fuels Further High-Growth High-Margin Biologics Mix Shift, As LT Targets Are Increased - ALERT": 2018 EBITDA Estimate

<sup>2) \$65.0</sup> is approximate revenue from the Cambrex press release "Cambrex Completes Acquisition of Avista Pharma Solutions"

<sup>3)</sup> AMPAC Fine Chemicals transaction EV is according to Korean Herald Source: S&P Capital IQ, as of end of Q3, 2019

# **CRO – Transaction Comps**

		CRO -	Transaction Comp	S					
in millions  Announced  Date	Target	Target Description	Buyer	Geographic Location	Enterprise Value	LTM Revenue	LTM EBITDA	EV / LTM Revenue	EV / LT
Oct-19	Clinical Trial Centers Alliance (The Alliance)	CNS Network and the Hassman Research Institute recently completed a strategic merger to form Apex Innovation Sciences, which in turn acquired The Alliance	Apex Innovation Sciences	USA	NA	NA	NA	NA	
	Site Business of BioClinica								
Feb-19	Citoxlab	Contract research laboratory that provides a range of preclinical services to the pharma industry	Charles River Laboratories International	France	\$510.0	NA	\$36.7	NA	1
Feb-18	MPI Research	Provides preclinical and early clinical contract research services	Charles River Laboratories International	USA	800.0	240.0	68.4	3.3x	1
Sep-17	Optimal Research	SMO providing solutions to CROs and pharmaceutical, biotechnology, and medical device companies	Synexus	USA	NA	NA	NA	NA	
Jul-17	MAPI Development	Non-clinical CRO that provides mission-critical research services and products	ICON	France	139.5	NA	NA	NA	
Jun-17	PAREXEL International	Outsourcing services company that provides clinical research, consulting, and commercialization	Pamplona Capital Management	USA	5,007.4	2,097.0	342.8	2.4x	1
Sep-16	ExecuPharm	Offers CRO support services including clinical trial management, monitoring, and site management	PAREXEL International	USA	155.0	NA	NA	NA	
May-16	Synexus	Engages in the identification, recruitment, and retention of patients for clinical trials on behalf of sponsors	Pharmaceutical Product Development	UK	257.8	68.8	15.9	3.7x	1
es:				Mediar	\$655.0	\$1,168.5	\$180.5	2.9x	1
Not Availab	le			Mear	2,588.3	1,278.8	249.9		
				Mir	32.9	26.8	15.9		
				Max	x 13,266.8	3,063.0	743.0		

# **Specialty Packaging – Transaction Comps**

		Specialty Pacl	kaging - Transacti	on Comps					
USD in millions  Announced  Date	Target	Target Description	Buyer	Geographic Location	Enterprise Value	LTM Revenue	LTM EBITDA	EV / LTM Revenue	EV / LTM EBITDA
Jun-19	Pregis Corporation	Pregis Corporation markets and supplies protective and specialty packaging solutions. The company operates in two segments: Protective Packaging and Specialty Packaging	Warburg Pincus	USA	\$1,300.0	NA	NA	NA	NA
Apr-19	Three manufacturing facilities of Amcor	Provides packaging for med devices; 3 facilities in EU previously owned by Bemis	Tekni-Plex	USA	215.0	\$100.0	NA	2.2x	NA
Jan-19	RPC Group	Packaging segment designs plastic packaging for end markets, including the food, beverage, personal care, and healthcare markets	Apollo Management	United Kingdom	5,728.2	5,056.4	\$764.0	1.1x	7.5x
Dec-18	Caraustar Industries	Manufactures and supplies recycled paperboard and converted paperboard products, including for pharmaceutical and healthcare markets	Greif Packaging	USA	1,800.0	1,376.0	174.0	1.3x	10.3x
Aug-18	Bemis Company	Manufactures and sells packaging products in medical and pharmaceutical markets globally	Amcor	USA	6,777.9	4,099.4	573.0	1.7x	11.8x
Jul-18	CSP Technologies	Manufactures and distributes custom polymeric products for the medical device, diagnostics, and pharmaceutical markets, among others	AptarGroup	USA	529.4	140.0	40.7	3.8x	13.0x
Jul-18	Expera Specialty Solutions	Specialty paper and packaging company in North America that offers food packaging papers	Ahlstrom Munksjo Oyj	USA	615.0	721.0	66.0	0.9x	9.3x
Jun-18	Papeles y Cartones de Europa	Manufactures and sells paper and corrugated cardboard packaging products in Europe	DS Smith	Spain	2,100.6	1,049.5	203.6	2.0x	10.3x
Jan-18	Foam Fabricators	Designs and manufactures molded and fabricated foam and packaging products	Compass Diversified Holdings	USA	247.5	126.0	30.0	2.0x	8.3x
Nov-17	PAC SERVICE	Manufactures customized packaging paperboards	Reno De Medici	Italy	17.7	24.1	2.2	0.7x	7.9x
Jan-17	Multi Packaging Solutions	Prints, manufactures, and sells paperboard, paper, and plastic packaging products globally	WestRock Company	USA	2,256.5	1,567.0	214.5	1.4x	10.5x
Notes: NA - Not Availab	nla			Median	\$1,300.0	\$885.2	\$174.0	1.5x	10.3x
Not rivaliab				Mean		1,425.9	229.8	1.7x	9.9x
				Min		24.1	2.2	0.7x	7.5x
				Max	6,777.9	5,056.4	764.0	3.8x	13.0x

# **Distribution – Transaction Comps**

		Distributi	on - Transaction C	comps					
in millions  Announced  Date	Target	Target Description	Buyer	Geographic Location	Enterprise Value	LTM Revenue	LTM EBITDA	EV / LTM Revenue	EV / LTN EBITDA
Aug-19	PCX International	PCX operates as a courier service agency in clinical trial industry	Marken Limited	Japan	NA	NA	NA	NA	
Jul-19	HRTL Logistic SRL / HETO Transport und Logistik GmbH / DER KURIER KFT	HRTL Logistic SRL comprises courier services business to the clinical trials industry. HETO Transport und Logistik GmbH and DER KURIER KFT. comprise clinical trial shipment activities	Marken Limited	Italy	NA	NA	NA	NA	
Aug-18	Aquilant	Aquilant Limited distributes and sells IV therapy, regional anesthesia and pain management products, and other devices for the medical and scientific sectors	H2 Equity Partners	United Kingdom	\$26.7	\$94.5	NA	0.3x	
Nov-17	H. D. Smith	Distributes and supplies healthcare products and business solutions to manufacturers and healthcare providers	AmerisourceBergen	USA	815.0	NA	NA	NA	
Nov-17	Cardinal Health (L)	Distributes pharmaceutical products, medical devices, and specialty pharmaceuticals to pharmacies and hospitals	Shanghai Pharma Century Global	Malaysia	557.0	3,845.7	\$83.3	0.1x	6
Mar-17	Pelion	Engages in the trade of pharmaceuticals, cosmetics, and parapharmaceuticals, operating through wholesale, retail, services, and other segments	Korporacja Inwestycyjna Polskiej Farmacji	Poland	323.4	\$2,399.5	\$31.5	0.1x	10
Aug-16	Anda	Distributes generic, branded, specialty, and over-the-counter pharmaceutical products	Teva Pharmaceutical Industries	USA	500.0	NA	NA	NA	
Jul-16	Pharmapar	Distributes generic drugs for privately insured individuals , offering a range of medication types	Alliance Pharma	Canada	11.1	\$17.3	NA	0.6x	
May-16	Symmetry Surgical	Manufactures and distributes medical devices worldwide	RoundTable Healthcare Partners	USA	129.5	84.1	\$9.1	1.5x	14
Mar-16	Rexall Pharma Plus	Operates a network of retail pharmacy stores in Canada, offering prescription centers that focus primarily on prescription and OTC products	McKesson Canada Corporation	Canada	2,154.3	\$2,000.0	\$200.0	1.1x	11
es:				Median	\$411.7	\$1,047.3	\$57.4	0.5x	10
- Not Availab	le			Mean	564.6	1,406.9	81.0	0.6x	10
				Min	11.1	17.3	9.1	0.1x	(
				Max	2,154.3	3,845.7	200.0	1.5x	1

#### **CDMO – Trading Comps**

				CDMC	- Trad	ing Coi	nps							
USD in millions				LTM		М	argin Analysis		Ent	erprise Value	/		Debt/	
Company	Ticker	Enterprise Value	Sales	EBITDA	EBIT	Gross Profit	EBITDA	EBIT	Sales	EBITDA	EBIT	Enterprise Value	Equity Value	EBITDA
Bachem Holding AG	SWX:BANB	\$2,049.0	\$313.7	\$85.0	\$62.7	29.5%	27.1%	20.0%	6.5x	24.1x	32.7x	5.7%	6.0%	1.4
Balchem Corporation	NasdaqGS:BCPC	3,405.3	637.2	151.2	107.6	31.8%	23.7%	16.9%	5.3x	22.5x	31.7x	7.0%	7.4%	1.6
Cambrex Corporation	NYSE:CBM	2,497.8	574.1	146.6	94.8	34.4%	25.5%	16.5%	4.4x	17.0x	26.3x	22.0%	27.4%	3.8
Catalent, Inc.	NYSE:CTLT	9,584.5	2,518.0	542.9	314.3	32.0%	21.6%	12.5%	3.8x	17.7x	30.5x	30.9%	42.5%	5.5
Consort Medical plc	LSE:CSRT	582.0	397.4	70.7	53.4	13.5%	17.8%	13.4%	1.5x	8.2x	10.9x	24.8%	31.7%	2.0
Eurofins Scientific SE	ENXTPA:ERF	11,963.8	4,785.5	845.4	500.0	19.4%	17.7%	10.4%	2.5x	14.2x	23.9x	33.7%	48.8%	4.8
Johnson Matthey Plc	LSE:JMAT	8,338.7	13,992.9	925.9	722.8	9.5%	6.6%	5.2%	0.6x	9.0x	11.5x	20.6%	23.7%	1.9
Lonza Group Ltd	SWX:LONN	28,562.0	5,863.9	1,545.4	1,057.6	38.8%	26.4%	18.0%	4.9x	18.5x	27.0x	13.6%	15.4%	2.5
Recipharm AB (publ)	OM:RECI B	1,336.3	733.8	110.5	39.5	69.3%	15.1%	5.4%	1.8x	12.1x	33.8x	38.7%	57.2%	4.7
Siegfried Holding AG	SWX:SFZN	1,701.3	831.1	132.8	82.7	20.6%	16.0%	9.9%	2.0x	12.8x	20.6x	5.1%	5.3%	0.73
Thermo Fisher Scientific Inc.	NYSE:TMO	134,118.6	24,868.0	6,331.0	4,084.0	44.6%	25.5%	16.4%	5.4x	21.2x	32.8x	14.7%	16.9%	3.1
West Pharmaceutical Services, Inc.	NYSE:WST	10,404.9	1,767.4	378.9	274.6	32.4%	21.4%	15.5%	5.9x	27.5x	37.9x	2.6%	2.6%	0.7
								_						
					Median	31.9%	21.5%	14.5%	4.1x	17.3x	28.8x	17.6%	20.3%	2.3
					Mean	31.3%	20.4%	13.4%	3.7x	17.1x	26.6x	18.3%	23.8%	2.7
					Min	9.5%	6.6%	5.2%	0.6x	8.2x	10.9x	2.6%	2.6%	0.7
					Max	69.3%	27.1%	20.0%	6.5x	27.5x	37.9x	38.7%	57.2%	5.5

- The median EV multiples for CDMOs at the end of Q3 were 4.1x and 17.3x for Sales and EBITDA, respectively
- Expansion amongst the largest CDMO players, especially in the biologics market, persisted throughout Q3 2019 as manufacturers attempt to meet customer demand
  - Many CDMOs have announced recent investments in their facilities to expand capabilities and/or increase capacity
  - Fujifilm's \$890mm investment in Biogen's biologics facility sheds light on the overall industry strategy of acquiring scale-up capabilities to improve efficiencies within biologics manufacturing processes
- Early-stage development capabilities remain a key importance that give larger one-stop-shop CDMOs a cost advantage during the scale-up process

#### **CRO – Trading Comps**

USD in millions				00		ng Com									
USD III Millions		_	LTM Margin Analysis						Ent	erprise Value,	/	Debt/			
Company	Ticker	Enterprise Value	Sales	EBITDA	EBIT	Gross Profit	EBITDA	EBIT	Sales	EBITDA	EBIT	Enterprise Value	Equity Value	EBITDA	
Charles River Laboratories International	NYSE:CRL	\$8,461.2	\$2,449.0	\$541.2	\$361.5	36.6%	22.1%	14.8%	3.5x	15.6x	23.4x	26.0%	34.1%	4.13	
ICON Public Limited Company	NasdaqGS:ICLR			470.4											
IQVIA Holdings Inc.	NYSE:IQV	40,253.7	10,706.0	1,857.0	870.0	34.9%	17.3%	8.1%	3.8x	21.7x	46.3x	29.8%	41.0%	6.5>	
	TSE:2183														
Medpace Holdings, Inc.	NasdaqGS:MEDP	3,033.7	786.2	151.0	118.7	63.8%	19.2%	15.1%	3.9x	20.1x	25.5x	1.8%	1.8%	0.4>	
PRA Health Sciences, Inc.	NasdaqGS:PRAH		2,932.6			48.8%								2.9>	
Syneos Health, Inc.	Nasdaq:SYNH	8,459.7	4,546.2	565.0	304.9	21.9%	12.4%	6.7%	1.9x	15.0x	27.7x	36.2%	55.6%	5.4>	
					Median	34.9%	17.3%	11.9%	3.0x	16.1x	23.4x	22.6%	23.4%	3.0>	
					Mean	38.4%	17.1%	11.8%	2.9x	16.9x	26.0x	20.0%	26.1%	3.3>	
					Min	21.9%	12.4%	6.7%	1.9x	13.1x	18.4x	1.8%	1.8%	0.4>	
					Max	63.8%	22.1%	15.1%			46.3x	36.2%	55.6%	6.5	

- The median EV multiples for CROs were 3.0x and 16.1x for Sales and EBITDA, respectively
- Since 2017, there has been a strong trend of consolidation in the CRO space. Strategic acquirers and private equity investors continue to show robust interest in the space
- The growth in the biosimilars and biologics markets, adoption of new technologies, rising demand for specialized testing services, and the emerging Asian markets further drive the CRO market<sup>1</sup>
- While we haven't seen 'megadeals' in 2019 in the CRO space (unlike with CDMOs), M&A activity for smaller, bolt-on acquisitions has remain strong through Q3
  - Pharma companies look to large CROs for more expansive, global clinical trials but there is still a need for small- to mid-sized CROs who specialize in very focused indications such as immunology and oncology

#### **Specialty Packaging – Trading Comps**

USD in millions			LTM Margin Analysis						Fnt	erprise Value	,	Debt/			
Company	Ticker	Enterprise Value	Sales	EBITDA	EBIT	Gross Profit	EBITDA	EBIT	Sales	EBITDA	EBIT	Enterprise Value	Equity Value	EBITDA	
Amcor plc	ASX:AMC	\$21,022.7	\$9,458.2	\$1,316.2	\$938.3	19.0%	13.9%	9.9%	2.2x	16.0x	22.4x	29.0%	39.3%	4.6x	
AptarGroup, Inc.	NYSE:ATR	8,629.4	2,837.9	582.6	398.6	36.0%	20.5%	14.0%	3.0x	14.8x	21.6x	15.6%	17.8%	2.3x	
Berry Global Group, Inc.	NYSE:BERY	10,479.6	7,913.0	1,333.0	795.0	18.4%	16.8%	10.0%	1.3x	7.9x	13.2x	52.9%	106.9%	4.2x	
CCL Industries Inc.	TSX:CCL.B	8,816.0	4,094.8	766.3	547.1	28.4%	18.7%	13.4%	2.2x	11.5x	16.1x	22.5%	27.6%	2.6x	
Gerresheimer AG	DB:GXI	631.5	1,571.5	322.8	161.6	29.0%	20.5%	10.3%	0.4x	2.0x	3.9x	119.7%	NM	2.3x	
Mondi plc	LSE:MNDI	11,952.8	8,562.8	1,998.2	1,500.9	45.5%	23.3%	17.5%	1.4x	6.0x	8.0x	23.0%	29.6%	1.4x	
Sonoco Products Company	NYSE:SON	7,588.2	5,431.8	736.2	503.4	19.5%	13.6%	9.3%	1.4x	10.3x	15.1x	24.5%	31.9%	2.5x	
West Pharmaceutical Services, Inc.	NYSE:WST	10,404.9	1,767.4	378.9	274.6	32.4%	21.4%	15.5%	5.9x	27.5x	37.9x	2.6%	2.6%	0.7x	
WestRock Company	NYSE:WRK	19,739.2	17,874.0	2,922.2	1,552.8	19.7%	16.3%	8.7%	1.1x	6.8x	12.7x	53.4%	112.3%	3.6x	
Winpak Ltd.	TSX:WPK	1,759.9	886.4	197.4	155.9	31.0%	22.3%	17.6%	2.0x	8.9x	11.3x	0.0%	0.0%	0.0x	
					Г										
					Median	28.7%	19.6%	11.8%	1.7x	9.6x	14.1x	23.8%	29.6%	2.4x	
					Mean	27.9%	18.7%	12.6%	2.1x	11.2x	16.2x	34.3%	40.9%	2.4x	
					Min	18.4%	13.6%	8.7%	0.4x	2.0x	3.9x	0.0%	0.0%	0.0x	

- The median EV multiples for Specialty Packaging were 1.7x and 9.6x for Sales and EBITDA, respectively
- Expect further consolidation as strategic buyers look to roll up niche capabilities and capacity and as private equity looks for cash flow reliable packagers from which to build a platform

23.3%

- The most successful pharma packagers experience sticky customer relationships and a steady revenue stream
- The new wave of medicines, including biologics and gene therapies, are pressuring packagers to acquire specialized capabilities such as cold-chain technologies and aseptic fill/finish operations


112.3%

## **Distribution – Trading Comps**

			D	istribut	ion - Tı	rading (	Comps							
USD in millions			LTM Margin Analysis						Ent	erprise Value	Debt/			
Company	Ticker	Enterprise Value	Sales	EBITDA	EBIT	Gross Profit	EBITDA	EBIT	Sales	EBITDA	EBIT	Enterprise Value	Equity Value	EBITDA
AmerisourceBergen Corporation	NYSE:ABC	\$18,657.9	\$177,248.5	\$2,282.0	\$1,769.7	2.7%	1.3%	NM	0.1x	8.2x	10.5x	24.2%	26.3%	2.0x
Cardinal Health, Inc.	NYSE:CAH	19,304.6	145,534.0	2,808.0	1,808.0	4.7%	1.9%	1.2%	0.1x	6.9x	10.7x	41.6%	58.2%	2.9x
Henry Schein, Inc.	NasdaqGS:HSIC	10,801.1	13,420.6	1,139.8	914.0	27.4%	8.5%	6.8%	0.8x	9.5x	11.8x	13.6%	15.6%	1.3x
McKesson Europe AG	HMSE:CLS1	5,985.0	23,767.5	208.4	93.3	9.6%	NM	NM	0.3x	NM	NM	18.5%	19.1%	5.3x
McKesson Corporation	NYSE:MCK	33,261.0	217,440.0	4,225.0	3,282.0	5.4%	1.9%	1.5%	0.2x	7.9x	10.1x	29.9%	39.3%	2.4x
Owens & Minor, Inc.	NYSE:OMI	2,182.9	9,953.4	207.1	102.8	14.6%	2.1%	1.0%	0.2x	10.5x	21.2x	87.4%	521.7%	9.2x
Patterson Companies, Inc.	NasdaqGS:PDCO	2,410.2	5,566.9	269.1	186.6	21.5%	4.8%	3.4%	0.4x	9.0x	12.9x	34.8%	49.8%	3.1x
UDG Healthcare plc	LSE:UDG	2,370.3	1,296.5	167.2	114.3	28.9%	12.9%	8.8%	1.8x	14.2x	20.7x	10.2%	10.5%	1.4x
NM - Not Meaningful					Median	12.1%	2.1%	2.4%	0.2x	9. <b>0</b> x	11.8x	27.0%	32.8%	2.6x
					Mean	14.4%	4.8%	3.8%	0.5x	9.4x	14.0x	32.5%	92.6%	3.4x
					Min	2.7%	1.3%	1.0%	0.1x	6.9x	10.1x	10.2%	10.5%	1.3x
					Max	28.9%	12.9%	8.8%	1.8x	14.2x	21.2x	87.4%	521.7%	9.2

- The median EV multiples for Distribution were 0.2x and 9.0x for Sales and EBITDA, respectively
- Distributors look to streamline the supply chain, serving the entire continuum of care, including drug manufacturers, acute care, retailers, payors, and patients
- Increasing demand for pharmaceutical drugs in emerging markets is causing distributors to quickly implement global manufacturing supply chain networks

#### **Valuation Trends – Last 3 Years**



CDMO basket consists of: Bachem (SWX:BANB), Balchem (NasdaqGS:BCPC), Cambrex (NYSE:CBM), Catalent (NYSE:CTLT), Consort Medical plc (LSE:CSRT), Eurofins Scientific SE (ENXTPA:ERF), Johnson Matthey Plc (LSE:JMAT), Lonza (SWX:LONN), Recipharm AB (OM:RECI B), Siegfried (SWX:SFZN), Thermo Fisher Scientific Inc. (NYSE:TMO), and West Pharmaceutical Services, Inc. (NYSE:WST)

CRO basket consists of: Charles River (NYSE:CRL), ICON (NasdaqGS:ICLR), IQVIA (NYSE:IQV), Medpace (NasdaqGS:MEDP), PRA Health Sciences (NasdaqGS:PRAH), and Syneos Health, Inc. (NasdawGS:SYNH)


Distribution basket consists of: AmerisourceBergen (NYSE:ABC), Cardinal Health (NYSE:CAH), Henry Schlein (NasdaqGS:HSIC), McKesson Europe (HMSE:CLS1), McKesson (NYSE:MCK), Owens & Minor (NYSE:OMI), Patterson Companies (NasdaqGS:PDCO), and UDG Healthcare (LSE:UDG)

Packaging basket consists of: Amcor Limited (ASX:AMC), AptarGroup, Inc. (NYSE:ATR), Berry Global Group, Inc. (NYSE:BERY), CCL Industries Inc. (TSX:CCL.B), Gerresheimer AG (DB:GXI), Mondi plc (LSE:MNDI), RPC Group plc (LSE:RPC), Sonoco Products Company (NYSE:SON), West Pharmaceutical Services, Inc. (NYSE:WST), WestRock Company (NYSE:WRK), and Winpak Ltd. (TSX:WPK)

## Valuation Trends (Current, 3 Year, & LTM Comparisons)

- Below are the current EV / EBITDA multiples for each sector:
  - CDMO: 19.1x (46.5% above current S&P multiples)
  - CRO: 18.7x (43.4% above current S&P multiples)
  - Specialty Packaging: 9.6x (26.3% below current S&P multiples)
  - Distribution: 8.7x (33.6% below current S&P multiples)
  - S&P 500: 13.0x
- Below are the average EV / EBITDA multiples for each sector over the last 3 years:
  - CDMO: 17.6x (42.6% above average S&P multiples)
  - CRO: 18.1x (46.2% above average S&P multiples)
  - Specialty Packaging: 10.4x (16.1% below average S&P multiples)
  - Distribution: 9.7x (21.9% below average S&P multiples)
  - ─ S&P 500: 12.4x
- Below are the % change in EV / EBITDA multiples for each sector over the last 3 years (and LTM):
  - CDMO: +21.3% (up 3.0% in the last 12 months)
  - CRO: +3.7% (down 1.5% in the last 12 months)
  - Specialty Packaging: -5.3% (down 3.4% in the last 12 months)
  - Distribution: -13.2% (down 11.6% in the last 12 months)
  - S&P 500: +14.7% (down 0.1% in the last 12 months)

#### **Valuation Trends – Last 5 Years**



CDMO basket consists of: Bachem (SWX:BANB), Balchem (NasdaqGS:BCPC), Cambrex (NYSE:CBM), Catalent (NYSE:CTLT), Consort Medical plc (LSE:CSRT), Eurofins Scientific SE (ENXTPA:ERF), Johnson Matthey Plc (LSE:JMAT), Lonza (SWX:LONN), Recipharm AB (OM:RECI B), Siegfried (SWX:SFZN), Thermo Fisher Scientific Inc. (NYSE:TMO), and West Pharmaceutical Services, Inc. (NYSE:WST)

CRO basket consists of: Charles River (NYSE:CRL), ICON (NasdaqGS:ICLR), IQVIA (NYSE:IQV), Medpace (NasdaqGS:MEDP), PRA Health Sciences (NasdaqGS:PRAH), and Syneos Health, Inc. (NasdawGS:SYNH)

Distribution basket consists of: AmerisourceBergen (NYSE:ABC), Cardinal Health (NYSE:CAH), Henry Schlein (NasdaqGS:HSIC), McKesson Europe (HMSE:CLS1), McKesson (NYSE:MCK), Owens & Minor (NYSE:OMI), Patterson Companies (NasdaqGS:PDCO), and UDG Healthcare (LSE:UDG)

Packaging basket consists of: Amcor Limited (ASX:AMC), AptarGroup, Inc. (NYSE:ATR), Berry Global Group, Inc. (NYSE:BERY), CCL Industries Inc. (TSX:CCL.B), Gerresheimer AG (DB:GXI), Mondi plc (LSE:MNDI), RPC Group plc (LSE:RPC), Sonoco Products Company (NYSE:SON), West Pharmaceutical Services, Inc. (NYSE:WST), WestRock Company (NYSE:WRK), and Winpak Ltd. (TSX:WPK)

## Valuation Trends (Current, 5 Year, & LTM Comparisons)

- Below are the average EV / EBITDA multiples for each sector over the last 5 years:
  - CDMO: 16.7x (43.1% above average S&P multiples)
  - CRO: 16.3x (39.6% above average S&P multiples)
  - Specialty Packaging: 10.2x (12.2% below average S&P multiples)
  - Distribution: 10.8x (7.3% below average S&P multiples)
  - S&P 500: 11.7x
- Below are the % change in EV / EBITDA multiples for each sector over the last 5 years (and LTM):
  - CDMO: +27.3% (up 5.0% in the last 12 months)
  - CRO: +44.6% (up 1.7% in the last 12 months)
  - Specialty Packaging: +14.4% (up 8.6% in the last 12 months)
  - Distribution: -36.1% (down 1.4% in the last 12 months)
  - S&P 500: +36.4% (up 4.5% in the last 12 months)